Sweetch Health App for Chronic Disease Management Get latest price

Sweetch Health App for Chronic Disease Management

Sweetch Health App for Chronic Disease Management

Sweetch Health App for Chronic Disease Management

Sweetch Health App for Chronic Disease Management

Sweetch Health App for Chronic Disease Management

Sweetch Health App for Chronic Disease Management

47 Recent Views In Stock

The Problem

Almost 50% of adults living in developed countries have chronic disease. The World Health Organization indicates that only about 50% of patients with chronic diseases follow treatment recommendations, and only about 20% follow disease prevention recommendations.
Chronic diseases account for 86% of all healthcare spending. Raising adherence to disease prevention and disease management recommendations has greater impact on public health than any improvement in specific medical care.

 

Sweetch's Solution - a unique personalised experience that can be scaled

In a mobile-first world, people are always connected – but not always available and attentive. Sweetch is a clinically validated Patient Engagement Platform that utilises Artificial Intelligence (AI) to significantly increase patients’ adherence to essential health promotion, disease prevention and disease management recommendations in a highly personalised and scalable way. Sweetch is HIPAA, GDPR and Australian Privacy Act compliant.

 

Deep Tech – Combining Advanced Data Science with Behavioural Modification

Designed to work in real life, Sweetch’s AI-powered Behavioural Intelligence Engine converts millions of data points originating from a patient's smart phone and other connected devices into contextual, hyper-personalised, just-in-time, just-in-place, recommendations. Through analysing the patient’s current context, past behaviours and real-world capabilities, Sweetch’s proprietary algorithms identify the individual’s compliance patterns and continuously optimise the recommendations that each patient receives. Sweetch’s Just-in-Time Adaptive Intervention approach leads to significantly improved engagement and ultimately improved health outcomes.

 

Clinical Outcomes

In a clinical trial conducted by Johns Hopkins, Sweetch achieved 86% patient retention and clinically significant effects on weight loss, physical activity increase, and Hemoglobin A1C reduction. Based on these outstanding results, the Hopkins researchers are now commencing a large NIH-funded randomised controlled study.

https://www.jmir.org/2018/2/e72/

 

One Dynamic Platform for Multiple Chronic Conditions

As an AI-powered solution, Sweetch enables seamless customisation to different disease domains. Sweetch is currently being deployed in four verticals:

1. Cardiovascular and Metabolic Areas – Diabetes, Pre-diabetes, Obesity, Coronary Artery Disease, and Atrial Fibrillation;
2. Oncology – Breast Cancer and Prostate Cancer;
3. Autoimmune Diseases – Rheumatoid Arthritis and IBD; and
4. Population Health.

 

Differentiation

1. Deep tech – developed by a leading team of data scientists over the last 5 years, Sweetch is the first mobile health platform to combine predictive analytics and behavioural modification (provisional patent application P-79151-USP3).
2. Scalability – fully automated patient engagement platform uniquely positioned for global scaling.
3. Flexibility – seamless customisation to different disease domains and corporate partners.
4. High cost-efficiency – outcome-based business model.
5. Unique Data Asset – by integrating patients’ behavioural data, patients reported outcomes, biometric measures, treatment adherence patterns, and clinical outcomes, Sweetch creates a unique data asset that doesn’t exist today with significant implications on chronic disease prevention and management.

 

Global Traction

Sweetch’s business partners include Insurers, Pharma Companies, Healthcare Providers, Self-insured Employers and Patient Support Programs spanning across the US, the EU, and APAC. These include, among others –

• Siemens Healthineers;
• WellSpan Health – one of the largest integrated health care systems in Pennsylvania - https://www.prnewswire.com/news-releases/ai-mobile-health-app-sweetch-partners-with-wellspan-health-to-help-fight-diabetes-300741126.html
• Leading global pharma companies – Roche, Sanofi, Janssen, and Novo Nordisk;
• The Baker Institute – Australia’s leading Heart & Diabetes Clinical and ResearchInstitute;
• The National Association of Chronic Disease Directors;
• Icon Group – one of the largest cancer care networks in APAC;
• EMIS – UK’s most popular clinical system (referenced as React2D) - https://www.mobihealthnews.com/content/europe/iqvia-emis-health-partner-support-gps-england-electronically-prescribe-apps-patients

Read more...

To contact Sweetch about Sweetch Health App for Chronic Disease Management use Get a quote.

The Problem

Almost 50% of adults living in developed countries have chronic disease. The World Health Organization indicates that only about 50% of patients with chronic diseases follow treatment recommendations, and only about 20% follow disease prevention recommendations.
Chronic diseases account for 86% of all healthcare spending. Raising adherence to disease prevention and disease management recommendations has greater impact on public health than any improvement in specific medical care.

 

Sweetch's Solution - a unique personalised experience that can be scaled

In a mobile-first world, people are always connected – but not always available and attentive. Sweetch is a clinically validated Patient Engagement Platform that utilises Artificial Intelligence (AI) to significantly increase patients’ adherence to essential health promotion, disease prevention and disease management recommendations in a highly personalised and scalable way. Sweetch is HIPAA, GDPR and Australian Privacy Act compliant.

 

Deep Tech – Combining Advanced Data Science with Behavioural Modification

Designed to work in real life, Sweetch’s AI-powered Behavioural Intelligence Engine converts millions of data points originating from a patient's smart phone and other connected devices into contextual, hyper-personalised, just-in-time, just-in-place, recommendations. Through analysing the patient’s current context, past behaviours and real-world capabilities, Sweetch’s proprietary algorithms identify the individual’s compliance patterns and continuously optimise the recommendations that each patient receives. Sweetch’s Just-in-Time Adaptive Intervention approach leads to significantly improved engagement and ultimately improved health outcomes.

 

Clinical Outcomes

In a clinical trial conducted by Johns Hopkins, Sweetch achieved 86% patient retention and clinically significant effects on weight loss, physical activity increase, and Hemoglobin A1C reduction. Based on these outstanding results, the Hopkins researchers are now commencing a large NIH-funded randomised controlled study.

https://www.jmir.org/2018/2/e72/

 

One Dynamic Platform for Multiple Chronic Conditions

As an AI-powered solution, Sweetch enables seamless customisation to different disease domains. Sweetch is currently being deployed in four verticals:

1. Cardiovascular and Metabolic Areas – Diabetes, Pre-diabetes, Obesity, Coronary Artery Disease, and Atrial Fibrillation;
2. Oncology – Breast Cancer and Prostate Cancer;
3. Autoimmune Diseases – Rheumatoid Arthritis and IBD; and
4. Population Health.

 

Differentiation

1. Deep tech – developed by a leading team of data scientists over the last 5 years, Sweetch is the first mobile health platform to combine predictive analytics and behavioural modification (provisional patent application P-79151-USP3).
2. Scalability – fully automated patient engagement platform uniquely positioned for global scaling.
3. Flexibility – seamless customisation to different disease domains and corporate partners.
4. High cost-efficiency – outcome-based business model.
5. Unique Data Asset – by integrating patients’ behavioural data, patients reported outcomes, biometric measures, treatment adherence patterns, and clinical outcomes, Sweetch creates a unique data asset that doesn’t exist today with significant implications on chronic disease prevention and management.

 

Global Traction

Sweetch’s business partners include Insurers, Pharma Companies, Healthcare Providers, Self-insured Employers and Patient Support Programs spanning across the US, the EU, and APAC. These include, among others –

• Siemens Healthineers;
• WellSpan Health – one of the largest integrated health care systems in Pennsylvania - https://www.prnewswire.com/news-releases/ai-mobile-health-app-sweetch-partners-with-wellspan-health-to-help-fight-diabetes-300741126.html
• Leading global pharma companies – Roche, Sanofi, Janssen, and Novo Nordisk;
• The Baker Institute – Australia’s leading Heart & Diabetes Clinical and ResearchInstitute;
• The National Association of Chronic Disease Directors;
• Icon Group – one of the largest cancer care networks in APAC;
• EMIS – UK’s most popular clinical system (referenced as React2D) - https://www.mobihealthnews.com/content/europe/iqvia-emis-health-partner-support-gps-england-electronically-prescribe-apps-patients

Read less...

To contact Sweetch about Sweetch Health App for Chronic Disease Management use Get a quote.